Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value.
Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, Wang J, Ou FS, Innocenti F, Mumenthaler SM, Jayachandran P, Kawanishi N, Lenz A, Soni S, Algaze S, Zhang W, Khoukaz T, Roussos Torres E, Seeber A, Abraham JP, Lou E, Philip PA, Weinberg BA, Shields AF, Goldberg RM, Marshall JL, Venook AP, Korn WM, Lenz HJ. Battaglin F, et al. Among authors: kawanishi n. J Immunother Cancer. 2024 Jan 11;12(1):e007939. doi: 10.1136/jitc-2023-007939. J Immunother Cancer. 2024. PMID: 38212126 Free PMC article.
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer.
Arai H, Xiao Y, Loupakis F, Kawanishi N, Wang J, Battaglin F, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Falcone A, Millstein J, Lenz HJ. Arai H, et al. Among authors: kawanishi n. J Immunother Cancer. 2020 Nov;8(2):e001714. doi: 10.1136/jitc-2020-001714. J Immunother Cancer. 2020. PMID: 33172883 Free PMC article.
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.
Arai H, Elliott A, Millstein J, Xiu J, Ou FS, Innocenti F, Wang J, Battaglin F, Jayachandran P, Kawanishi N, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Lockhart AC, Shields AF, Abraham JP, Magee D, Stafford P, Zhang J, Venook AP, Korn WM, Lenz HJ. Arai H, et al. Among authors: kawanishi n. Oncogene. 2022 Jan;41(2):260-267. doi: 10.1038/s41388-021-02074-z. Epub 2021 Nov 2. Oncogene. 2022. PMID: 34728807 Free PMC article.
Molecular Characterization of Appendiceal Goblet Cell Carcinoid.
Arai H, Baca Y, Battaglin F, Kawanishi N, Wang J, Soni S, Zhang W, Millstein J, Johnston C, Goldberg RM, Philip PA, Seeber A, Xiu J, Hwang JJ, Shields AF, Marshall JL, Korn WM, Lenz HJ. Arai H, et al. Among authors: kawanishi n. Mol Cancer Ther. 2020 Dec;19(12):2634-2640. doi: 10.1158/1535-7163.MCT-20-0318. Epub 2020 Oct 9. Mol Cancer Ther. 2020. PMID: 33037134 Free PMC article.
The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer.
Arai H, Elliott A, Xiu J, Wang J, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Marshall JL, Lockhart AC, Stafford P, Zhang J, Moretto R, Cremolini C, Korn WM, Lenz HJ. Arai H, et al. Among authors: kawanishi n. Clin Cancer Res. 2021 Jun 1;27(11):3234-3242. doi: 10.1158/1078-0432.CCR-20-3635. Epub 2021 Mar 25. Clin Cancer Res. 2021. PMID: 33766816
RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC.
Arai H, Cao S, Battaglin F, Wang J, Kawanishi N, Tokunaga R, Loupakis F, Stintzing S, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ. Arai H, et al. Among authors: kawanishi n. Mol Cancer Ther. 2021 Jun;20(6):1153-1160. doi: 10.1158/1535-7163.MCT-20-0649. Epub 2021 Mar 30. Mol Cancer Ther. 2021. PMID: 33785650
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.
Wang JY, Xiu J, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Shields AF, Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Oberley M, Spetzler D, Shen L, Korn WM, Lenz HJ. Wang JY, et al. Among authors: kawanishi n. Ann Oncol. 2021 Jul;32(7):906-916. doi: 10.1016/j.annonc.2021.03.203. Epub 2021 Mar 30. Ann Oncol. 2021. PMID: 33798656 Free article.
Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
Arai H, Millstein J, Loupakis F, Stintzing S, Wang J, Battaglin F, Kawanishi N, Jayachandran P, Soni S, Zhang W, Mumenthaler SM, Cremolini C, Heinemann V, Falcone A, Lenz HJ. Arai H, et al. Among authors: kawanishi n. Eur J Cancer. 2021 Jun;150:133-142. doi: 10.1016/j.ejca.2021.03.048. Epub 2021 Apr 23. Eur J Cancer. 2021. PMID: 33901792
Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.
Wang J, Xiu J, Baca Y, Battaglin F, Arai H, Kawanishi N, Soni S, Zhang W, Millstein J, Salhia B, Goldberg RM, Philip PA, Seeber A, Hwang JJ, Shields AF, Marshall JL, Astsaturov I, Craig Lockhart A, Gatalica Z, Michael Korn W, Lenz HJ. Wang J, et al. Among authors: kawanishi n. Oncogene. 2021 Jul;40(30):4894-4905. doi: 10.1038/s41388-021-01840-3. Epub 2021 Jun 23. Oncogene. 2021. PMID: 34163031
Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Arai H, Xiao Y, Millstein J, Wang J, Battaglin F, Kawanishi N, Jayachandran P, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Parikh AR, Lenz HJ. Arai H, et al. Among authors: kawanishi n. Br J Cancer. 2022 Jan;126(1):72-78. doi: 10.1038/s41416-021-01592-7. Epub 2021 Oct 23. Br J Cancer. 2022. PMID: 34689170 Free PMC article. Clinical Trial.
108 results